Trial Profile
An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ifebemtinib (Primary)
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 11 Feb 2019 Results published in the Targeted Oncology
- 11 Feb 2019 Results of two open-label, crossover substudies published in the Targeted Oncology
- 08 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.